Calcium Folinate Altan 50 mg powder for injectable solution EFG
folinic acid
Read the entire leaflet carefully before starting to use this medication, as it contains important information for you.
Contents of the leaflet:
Calcium Folinate Altan 50 mg contains calcium folinate, which belongs to the group of medications called detoxifying agents. It is the calcium salt of folinic acid and is related to folic acid vitamin.
Calcium Folinate Altan is indicated for:
Calcium Folinate Altan is presented in the form of powder for injectable solution, which can be administered intramuscularly or intravenously.
Calcium Folinate Altan should not be injected intrathecally (into the spine).
Do not use Calcium Folinate Altan 50 mg powder for injectable solution EFG:
Warnings and precautions
Consult your doctor, pharmacist, or nurse before using Calcium Folinate Altan.
Using other medications and Calcium Folinate Altan:
Tell your doctor or pharmacist if you are using, have recently used, or may need to use any other medication.
Certain medications may interact with calcium folinate; in these cases, it may be necessary to change the dose or interrupt treatment with one of them.
It is essential that you inform your doctor if you are taking or have recently taken any of the following medications:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
It is unlikely that your doctor will ask you to use a folic acid antagonist or fluorouracil while pregnant or breastfeeding. However, if you have used a folic acid antagonist during pregnancy or breastfeeding, this medication (calcium folinate) may be used to reduce its side effects.
Driving and using machines:
There is no evidence that Calcium Folinate Altan affects the ability to drive vehicles or use machines.
Calcium Folinate Altan 50 mg powder for injectable solution EFG contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per vial, i.e., it is essentially "sodium-free".
Follow your doctor's instructions for administering this medication exactly. If in doubt, consult your doctor or pharmacist.
Remember to have your medication administered to you.
Your doctor will indicate the duration of your treatment with Calcium Folinate Altan. Do not stop treatment before completing it, as you will not achieve the desired therapeutic effect.
Since this medication increases the toxicity of 5-fluorouracil, treatment with the combination of both should be supervised by an experienced doctor in the use of anticancer medications.
Calcium Folinate Altan should only be administered intravenously and intramuscularly. In the case of intravenous administration, no more than 160 mg of calcium folinate should be injected per minute due to the calcium content of the solution.
For intravenous perfusion, calcium folinate can be diluted with 0.9% sodium chloride solution or 5% glucose solution before use.
If you use more Calcium Folinate Altan 50 mg powder for injectable solution EFG than you should:
If you have been administered more Calcium Folinate Altan than you should, consult your doctor or pharmacist immediately. No significant harm has been reported in patients who have received significantly higher doses of calcium folinate than recommended.
If an overdose of the combination of 5-fluorouracil and calcium folinate occurs, the overdose instructions for 5-fluorouracil should be followed.
In case of overdose or accidental ingestion, consult the Toxicology Information Service. Phone 91 562 04 20.
If you forget to use Calcium Folinate Altan 50 mg powder for injectable solution EFG:
Do not use a double dose to make up for forgotten doses.
If you have any other questions about using this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone experiences them.
The following side effects may occur:
Uncommon side effects: may affect up to 1 in 100 people
Fever
Rare side effects: may affect up to 1 in 1,000 people
Insomnia, agitation, and depression after high doses.
Increased frequency of seizures in epileptics.
Gastrointestinal disorders after high doses.
Very rare side effects: may affect up to 1 in 10,000 people
Allergic reactions, including anaphylactoid reactions and urticaria.
Combination therapy with 5-fluorouracil:
Generally, the safety profile depends on the applied 5-fluorouracil regimen due to the increased toxicity induced by 5-fluorouracil.
Very common (may affect more than 1 in 10 people)
No increase in other 5-fluorouracil-induced toxicities (e.g., neurotoxicity).
Very common (may affect more than 1 in 10 people)
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use: https://www.notificaram.es.
By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Store below 25°C. Store in the original package to protect from light.
After dilution, chemical and physical stability has been demonstrated for 8 hours at 25°C.
Do not use this medication after the expiration date shown on the package after EXP. The expiration date is the last day of the month indicated.
Do not use this medication if you observe particles in suspension after reconstitution or if you observe discoloration.
Medications should not be disposed of through wastewater or household waste. Ask your pharmacist how to dispose of medication packages that you no longer need. This will help protect the environment.
Composition of Calcium Folinate Altan 50 mg powder for injectable solution EFG:
Appearance of the product and package contents:
Each package contains 1 vial of lyophilized powder.
Other presentations: 25 vials.
Not all package sizes may be marketed.
Marketing authorization holder:
Altan Pharmaceuticals, S.A.
C/ Cólquide, Nº 6. Portal 2, 1ª planta, oficina F
Edificio Prisma
28230 - Las Rozas (Madrid)
Spain
Manufacturer:
Altan Pharmaceuticals, S.A.
Avda. de la Constitución, 198-199, Polígono Industrial Monte Boyal
45950 Casarrubios del Monte (Toledo)
Spain
This medication is authorized in the Member States of the European Economic Area under the following names:
France: Folinate de Calcium Altan 50 mg powder for injectable solution
Folinate de Calcium Altan 350 mg powder for injectable solution
Date of the last revision of this leaflet:October 2020
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.es/
This information is intended only for healthcare professionals:
For intravenous and intramuscular administration only.In the case of intravenous administration, no more than 160 mg of calcium folinate should be injected per minute due to the calcium content of the solution.
For intravenous perfusion, calcium folinate can be diluted with 0.9% sodium chloride solution or 5% glucose solution before use.
Before administration, calcium folinate should be visually inspected. The injectable solution or perfusion should be a clear, yellowish solution. If it appears turbid or particles are observed, the solution should be discarded. The calcium folinate solution for injection or perfusion is intended for single use.
Incompatibilities
When using Calcium Folinate Altan, the following incompatibilities should be taken into account:
Storage after reconstitution
It is recommended that the reconstituted solution be administered immediately.